After back-to-back years of 20%-plus gains in 2023 and 2024, the S&P 500 is off to another strong start to 2025. However, the S&P 500's forward earnings multiple of 22 (as of Feb. 7) was also ...

We recently compiled a list of the Weak Earnings, Outlook Drag Shares of These 10 Firms on Thursday. In this article, we are ...

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Corbus Pharmaceuticals (CRBP – Research ...

The Trump administration's decision to pause enforcement of an anti-bribery law raised the specter that drugmakers could ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Royalty Pharma (RPRX – Research Report), ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

The grants have been the source of new treatments for cancer, heart disease, diabetes, strokes and H.I.V.; wonder drugs like ...

Mitsubishi Chemical Group has agreed to sell its pharmaceutical business to Bain Capital for more than $3 billion, in a bid to focus on its key chemical businesses. The Japanese chemical company said ...

Budget 2025 healthcare expectations: The Union Budget 2025 presents an opportunity to propel this sector toward innovation, self-reliance, and global leadership. The Pharma companies are seeking ...